Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus MAXAQUIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus MAXAQUIN.
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER vs MAXAQUIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
Fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
400 mg intravenously every 8 to 12 hours for most infections; 400 mg every 8 hours for severe/complicated infections.
400 mg orally once daily for 5-10 days; for complicated urinary tract infections, 400 mg orally once daily for 10-14 days.
None Documented
None Documented
Terminal elimination half-life is 3.5-5 hours in patients with normal renal function. Clinically, this supports twice-daily dosing. In severe renal impairment (CrCl <30 mL/min), half-life may extend to 6-9 hours, requiring dose adjustment.
Terminal elimination half-life is approximately 12 hours (range 10-14 hours), supporting twice-daily dosing for systemic infections.
Renal excretion accounts for approximately 50-70% of the dose as unchanged drug via glomerular filtration and tubular secretion; fecal excretion accounts for 15-25%, with about 20% as unchanged drug; biliary excretion contributes minimally (<5%).
Renal excretion of unchanged drug accounts for 70-80%; biliary/fecal elimination accounts for 20-30%.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic